Celgene has announced organizational changes that will position the company for continued long-term growth, effective March 1. Bob Hugin will serve as executive chairman. Hugin will continue to lead the board of directors and manage the strategic direction of the company. Mark Alles will be promoted to chief executive officer. Jacqualyn Fouse, Ph.D., will be promoted to president and chief operating officer. Scott Smith, president of immunology and inflammation, will assume an expanded leadership role.
Throughout Hugin’s nearly 17 years of managerial leadership, Celgene has achieved unprecedented growth and produced outstanding results. As executive chairman, Hugin will remain actively involved in key business matters, continuing to direct the long-term future of the company.”
“Bob Hugin is responsible for leading the transformation of Celgene into the global biopharmaceutical company that it is today,” said Michael D. Casey, Celgene’s lead independent director. “As CEO, Bob has delivered exceptional results and we are incredibly grateful that Bob will continue to lead the strategic direction of Celgene. In addition to being involved in key business matters, as executive chairman, Bob will increase his focus on the development of Celgene’s next generation of leaders, his advocacy work to improve patient access and outcomes and on identifying the next wave of novel therapies for Celgene investment.”
Alles is a three-decade industry veteran and has been with Celgene since 2004, most recently serving as president and COO. As president and COO, Alles integrated Celgene’s corporate operational functions in support of its global commercial franchises. Previously, Alles built and led Celgene’s hematology and oncology franchise.
Fouse joined Celgene in 2010 as chief financial officer and has excelled as both the leader of Celgene’s finance department and in her current role as president of Celgene’s hematology and oncology franchise. As president and COO, Fouse will focus on further enhancing Celgene’s commitment to operational excellence, driving exceptional performance across Celgene’s franchises and functions. Reporting to Fouse in this role will be Celgene’s corporate operational functions as well as the hematology and oncology and I&I franchises.
Smith, president of Celgene’s I&I franchise, will be appointed to chair Celgene’s global management committee. As chair, Smith will be responsible for the effective coordination of Celgene’s operational and strategic imperatives. Smith joined Celgene in 2008 and will continue to be responsible for building and leading Celgene’s I&I franchise.